Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib Biotech Investing
Mesoblast Licensee Files for Marketing Approval to Treat Epidermolysis Bullosa Pharmaceutical Investing
Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC Pharmaceutical Investing
PreveCeutical Announces Default Judgment Against Essos Corporate Services Inc. and Detona Capital Corp. Cannabis Investing News
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial Pharmaceutical Investing
